Vanguard Group Inc. Has $759.79 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Vanguard Group Inc. lowered its stake in Exelixis, Inc. (NASDAQ:EXEL) by 1.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,671,090 shares of the biotechnology company’s stock after selling 400,130 shares during the period. Vanguard Group Inc. owned approximately 10.45% of Exelixis worth $759,789,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Fisher Asset Management LLC lifted its holdings in Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Exelixis by 25.1% during the 4th quarter. Wellington Management Group LLP now owns 129,935 shares of the biotechnology company’s stock worth $3,117,000 after buying an additional 26,049 shares during the period. Goldman Sachs Group Inc. grew its stake in Exelixis by 0.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,048,809 shares of the biotechnology company’s stock valued at $25,161,000 after buying an additional 5,833 shares during the last quarter. Bridgefront Capital LLC raised its holdings in Exelixis by 111.3% in the 4th quarter. Bridgefront Capital LLC now owns 22,847 shares of the biotechnology company’s stock worth $548,000 after acquiring an additional 12,034 shares during the period. Finally, True Wealth Design LLC acquired a new position in Exelixis during the 4th quarter worth $828,000. Institutional investors own 85.27% of the company’s stock.

Insider Activity at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 10,923 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $21.37, for a total transaction of $233,424.51. Following the sale, the director now directly owns 338,948 shares of the company’s stock, valued at $7,243,318.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Exelixis news, Director Jack L. Wyszomierski sold 10,923 shares of the business’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $21.37, for a total value of $233,424.51. Following the transaction, the director now owns 338,948 shares of the company’s stock, valued at $7,243,318.76. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director George Poste sold 11,686 shares of the stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total value of $244,938.56. Following the sale, the director now owns 213,907 shares in the company, valued at approximately $4,483,490.72. The disclosure for this sale can be found here. Insiders sold 30,896 shares of company stock valued at $660,677 in the last ninety days. Insiders own 2.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EXEL. StockNews.com downgraded Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 4th. JMP Securities reiterated a “market outperform” rating and set a $27.00 price target on shares of Exelixis in a report on Wednesday, April 10th. William Blair restated an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. TD Cowen boosted their target price on shares of Exelixis from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of Exelixis in a report on Friday, May 3rd. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.13.

Exelixis Trading Up 2.2 %

Shares of EXEL opened at $22.20 on Friday. The stock has a market cap of $6.73 billion, a PE ratio of 34.69, a PEG ratio of 0.53 and a beta of 0.56. Exelixis, Inc. has a 1 year low of $18.64 and a 1 year high of $24.34. The stock has a 50 day simple moving average of $21.89 and a 200-day simple moving average of $22.33.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The company had revenue of $425.23 million for the quarter, compared to analyst estimates of $461.04 million. During the same quarter in the prior year, the company earned $0.12 earnings per share. The business’s revenue was up 4.0% compared to the same quarter last year. On average, sell-side analysts forecast that Exelixis, Inc. will post 1.15 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.